Prognostic factors determining survival in patients with node positive differentiated thyroid cancer: a retrospective cross‐sectional study

Gülçelik, Mehmet Ali; Özdemi̇r, Yavuz; Çolakoğlu, Muhammet Kadri; Camlibel, Mithat; Ağuş, Haluk

doi:10.1111/coa.12022

Cited by 14 publications

(25 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CLNM is common in DTC, with a frequency of 30-90% (17) and has been demonstrated to be closely associated with higher recurrence and poorer survival rates in patients with DTC (18). The majority of metastatic sites are located in central compartment lymph nodes, and complete central lymph node dissection has been identified to reduce the incidence of disease persistence, recurrence and mortality (19).…”

Section: Discussionmentioning

confidence: 99%

Clinical outcomes and associated factors of radioiodine-131 treatment in differentiated thyroid cancer with cervical lymph node metastasis

et al. 2018

View full text Add to dashboard Cite

Abstract. Cervical lymph node metastasis (CLNM) is common in differentiated thyroid cancer (DTC). Radioiodine-131 ( 131 I) treatment is recommended for the removal of residual thyroid tissue following thyroidectomy. To date, the effect of 131 I therapy on the outcomes of patients with DTC with CLNM is unclear. The aim of the present study was to evaluate the final outcome of patients with DTC with CLNM according to 131 I administration, and to analyze the factors that may affect clinical outcomes. A total of 357 patients with DTC with CLNM were recruited and divided into three groups: Those who received 2, 3 or 4 doses of 131 I therapy, respectively. Successful ablation was defined as levels of stimulated serum thyroglobulin <2 ng/ml in the absence of CLNM. The rates of successful ablation were 80.35 (229/285), 76.36 (42/55) and 70.59% (12/17) for patients who received 2, 3 and 4 doses, respectively. The patients with DTC with CLNM who were <45 years old, with tumor sizes <2 cm, solitary nodules and TNM stage I-II disease exhibited significantly higher rates of successful ablation compared with the patients who were ≥45 years old, with tumor size ≥2 cm, multiple nodules and stage III-IV disease. Multivariate analyses revealed that tumor size, number of nodules and TNM stage were independent risk factors associated with successful ablation in patients with DTC with CLNM who received 2 doses of 131 I therapy. 131 I administration is a useful therapy to eradicate cervical lymph node metastasis in patients with DTC, and may be preferentially indicated in patients with DTC with CLNM who are aged <45 years, with tumor sizes <2 cm, solitary nodules and lower TNM stages, in order to control and prevent recurrence and/or metastases.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical outcomes and associated factors of radioiodine-131 treatment in differentiated thyroid cancer with cervical lymph node metastasis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In addition, we found p53 expression to be associated with several characteristics well recognized as better prognosis factors such as tumor size, presence of a tumor capsule, presence of thyroiditis, absence of multifocal tumors, and absence of metastasis at the time of diagnosis [20, 21]. …”

Section: Discussionmentioning

confidence: 99%

P53 and Expression of Immunological Markers May Identify Early Stage Thyroid Tumors

Marcello

Morari

Cunha

et al. 2013

Clinical and Developmental Immunology

View full text Add to dashboard Cite

Background. Besides its major role in cell proliferation, DNA repair, and apoptosis, functional p53 protein is involved in the induction of antitumor cytotoxic-T-cell activity against carcinoma cells. We aimed to investigate p53 and immune cell markers utility as diagnostic and prognostic markers of differentiated thyroid cancer (DTC). Methods. ACIS-III system was used to evaluate p53 and immune cell markers including tumor-associated macrophages (TAM); CD68 and tumor-infiltrating lymphocytes (TIL) subsets such as CD3, CD4, CD8, and CD20 in 206 thyroid carcinomas, 105 benign nodules, and 18 normal tissues. Also, TP53 was sequenced in 78 out of 164 patients with papillary thyroid carcinoma. Results. P53 expression was observed more frequently in malignant than in benign lesions (P < 0.0001) and helped discriminate follicular patterned lesions. In addition, p53 was more frequent in smaller (P = 0.0015), unique tumors (P = 0.0286), with thyroiditis (P = 0.0486) and without metastasis at diagnosis (P = 0.0201). TAM was more frequent in P53 negative tumors (P = 0.002). Infiltration of CD8+ TIL was found in 61.7% of P53 positive and 25.6% of P53 negative DTC (P < 0.001). Conclusions. We suggest that p53 and CD8+ TIL immune profile analysis might be useful in DTC.

show abstract

“…Regional LM is a poor prognostic factor which aggravates the prognosis of patients with DTC. 2,3 Therefore, current guidelines recommend the removal of all clinically suspected LM regions. 18 However, preoperative imaging modality including CT, magnetic resonance imaging, ultrasonography and F-18 FDG PET/CT on cervical region showed low sensitivity (30%-40%) for detection of regional LM.…”

Section: Furthermore Evaluation Of Functional Vat Activity By F-18 Fdgmentioning

confidence: 99%

“…Cervical regional lymph node (LN) metastasis is common in differentiated thyroid cancer (DTC) including papillary and follicular thyroid cancer . The DTC with regional LN metastasis (LM) has been associated with poor survival and high recurrence rate than the node‐negative DTC . Therefore, regional LM is an important clinical prognostic factor in DTC treatment.…”

Section: Introductionmentioning

confidence: 99%

Functional visceral fat activity evaluated by preoperative F‐18 FDG PET/CT predicts regional lymph node metastasis in differentiated thyroid cancer

Pahk

Choi

Kim

2018

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

Prognostic factors determining survival in patients with node positive differentiated thyroid cancer: a retrospective cross‐sectional study

Abstract: Cervical node metastasis in thyroid carcinoma slightly reduces overall survival. Prognostic factors can help identify high-risk patients and point towards an adequate therapeutic approach.

Cited by 14 publications

References 31 publications

Clinical outcomes and associated factors of radioiodine-131 treatment in differentiated thyroid cancer with cervical lymph node metastasis

Clinical outcomes and associated factors of radioiodine-131 treatment in differentiated thyroid cancer with cervical lymph node metastasis

P53 and Expression of Immunological Markers May Identify Early Stage Thyroid Tumors

Functional visceral fat activity evaluated by preoperative F‐18 FDG PET/CT predicts regional lymph node metastasis in differentiated thyroid cancer

Contact Info

Product

Resources

About